Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11029945 | 0.86 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL4464854 | 0.70 | CYP4F2 (0.37) | EPHX2CYP2D6MEN1CYP1A2CYP3A4 | |
| SCHEMBL7452059 | 0.68 | PRKCA (0.33) | — | |
| SCHEMBL21806005 | 0.68 | NAAA (0.36) | — | |
| SCHEMBL11782221 | 0.67 | POLB (0.33) | — | |
| SCHEMBL11782212 | 0.67 | POLB (0.33) | — | |
| SCHEMBL11782232 | 0.67 | POLB (0.33) | — | |
| SCHEMBL2053235 | 0.67 | AKR1B1 (0.37) | MEN1KMT2A | |
| SCHEMBL2946123 | 0.67 | EPHX2 (0.35) | EPHX2 | |
| SCHEMBL1289740 | 0.66 | PKM (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| EP-0068999-B1 | DERIVATIVES OF 1-ARYL-2-AMINOMETHYL-CYCLOPROPANE-CARBOXAMIDES (Z), THEIR PREPARATION AND THEIR USE AS MEDICINES IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | PIERRE FABRE S.A. (FR) | 1985-05-22 | — | — | EP | claimed |
| JP-3056415-A | — | — | None | — | — | JP | disclosed |
| WO-2015044962-A1 | AMORPHOUS FORM OF LEVOMILNACIPRAN HYDROCHLORIDE AND HYDRATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2015-04-02 | — | — | WO | disclosed |
| WO-2014009767-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 1-ARYL 2-AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE (Z) DERIVATIVES, THEIR ISOMERS AND SALTS | MICRO LABS LIMITED (IN) | 2014-01-16 | — | — | WO | disclosed |
| US-20130281523-A1 | LOW DOSE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2013-10-24 | — | — | US | disclosed |
| US-20120231083-A1 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-09-13 | — | — | US | disclosed |
| US-8178496-B2 | Photoreactive regulator of glutamate receptor function and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011063164-A2 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | STEADY SLEEP RX CO., INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2010036773-A8 | DEUTERATED 1-ARYL-2 -AMINOMETHYL CYCLOPROPANE CARBOXYAMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | disclosed |
| US-20030050224-A1 | Blocking glutamate function at an ionotropic glutamate receptor. e.g., N-methyl-D-aspartate receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptor and the kainate receptor; brain disorders; spinal chord | NEDERGAARD MAIKEN (US) | 2003-03-13 | — | — | US | disclosed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | disclosed |
| US-5596019-A | N-acyl-cycloalkylamine derivatives as melatonergics | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| JP-H0356415-A | CELL-PROTECTING AGENT FOR ISCHEMIC CEREBRAL CELL DISORDER | TOYO JOZO CO LTD | 1991-03-12 | — | — | JP | disclosed |
| EP-0068999-B1 | DERIVATIVES OF 1-ARYL-2-AMINOMETHYL-CYCLOPROPANE-CARBOXAMIDES (Z), THEIR PREPARATION AND THEIR USE AS MEDICINES IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | PIERRE FABRE S.A. (FR) | 1985-05-22 | — | — | EP | disclosed |
| EP-0068999-A1 | Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (Z), their preparation and their use as medicines in the treatment of disorders of the central nervous system | PIERRE FABRE S.A. (FR) | 1983-01-05 | — | — | EP | disclosed |